Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates

Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.

Abstract

We evaluated the in vitro activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -susceptible Staphylococcus aureus. Apramycin demonstrated an MIC50/MIC90 of 8/16 μg/mL. No strains had an MIC above the epidemiological cutoff value of 32 μg/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum in vitro activity of apramycin against S. aureus and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted.

Keywords: Activity spectrum; Aminoglycoside; Antibiotic; Apramycin; Gentamicin; Natural product; Repurposing; Staphylococcus aureus; Synergy.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Humans
  • Methicillin / pharmacology
  • Methicillin Resistance
  • Nebramycin / analogs & derivatives*
  • Nebramycin / pharmacology
  • Staphylococcal Infections / microbiology*
  • Staphylococcus aureus / drug effects*
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Nebramycin
  • apramycin
  • Vancomycin
  • Methicillin